ITD- and FL-induced FLT3 signal transduction leads to increased C/EBPβ-LIP expression and LIP/LAP ratio by different signalling modules

British Journal of Haematology

Volumn 148, Issue 5, 2010, Pages 777-790

  Haas, Sandra C ^a   Huber, René ^a   Gutsch, Romina ^a   Kandemir, Judith D ^a   Cappello, Christian ^a   Krauter, Jürgen ^a   Duyster, Justus ^b   Ganser, Arnold ^a   Brand, Korbinian ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Acute myeloid leukaemia; C EBP ; FLT3 ITD; Mammalian target of rapamycin; P90 ribosomal S6 kinase

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN BETA; CD135 ANTIGEN; CELL PROTEIN; FLT3 LIGAND; PROTEIN LAP; PROTEIN LIP; RAPAMYCIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE DUPLICATION; HUMAN; HUMAN CELL; INTERNAL TANDEM DUPLICATION; LEUKEMIA CELL; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA TRANSLATION; SIGNAL TRANSDUCTION;

ADULT; AGED; AGED, 80 AND OVER; CCAAT-ENHANCER-BINDING PROTEIN-BETA; CELL PROLIFERATION; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; IMMUNOBLOTTING; LEUKEMIA, MYELOID, ACUTE; MALE; MEMBRANE PROTEINS; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TANDEM REPEAT SEQUENCES; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 76449083361     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2009.08012.x     Document Type: Article

References (45)

1. Akashi, K., Traver, D. Zon, L.I. (2005) The complex cartography of stem cell commitment. Cell, 121, 160 162.
2. Anjum, R. Blenis, J. (2008) The RSK family of kinases: emerging roles in cellular signalling. Nature Reviews Molecular Cell Biology, 9, 747 758.
3. Baumgartner, B., Weber, M., Quirling, M., Fischer, C., Page, S., Adam, M., Von Schilling, C., Waterhouse, C., Schmid, C., Neumeier, D. Brand, K. (2002) Increased IkappaB kinase activity is associated with activated NF-kappaB in acute myeloid blasts. Leukemia, 16, 2062 2071.
4. Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A., Gralnick, H.R. Sultan, C. (1976) Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. British Journal of Haematology, 33, 451 458.
5. Bhaskar, P.T. Hay, N. (2007) The two TORCs and Akt. Developmental Cell, 12, 487 502.
6. Calkhoven, C.F., Muller, C. Leutz, A. (2000) Translational control of C/EBPalpha and C/EBPbeta isoform expression. Genes & Development, 14, 1920 1932.
7. Cappello, C., Saugel, B., Huth, K.C., Zwergal, A., Krautkramer, M., Furman, C., Rouis, M., Wieser, B., Schneider, H.W., Neumeier, D. Brand, K. (2007) Ozonized low density lipoprotein (ozLDL) inhibits NF-kappaB and IRAK-1-associated signaling. Arteriosclerosis, Thrombosis, and Vascular Biology, 27, 226 232.
8. Fenski, R., Flesch, K., Serve, S., Mizuki, M., Oelmann, E., Kratz-Albers, K., Kienast, J., Leo, R., Schwartz, S., Berdel, W.E. Serve, H. (2000) Constitutive activation of FLT3 in acute myeloid leukaemia and its consequences for growth of 32D cells. British Journal of Haematology, 108, 322 330.
9. Gilliland, D.G. Griffin, J.D. (2002) The roles of FLT3 in hematopoiesis and leukemia. Blood, 100, 1532 1542.
10. Grant, S. (2008) Cotargeting survival signaling pathways in cancer. The Journal of Clinical Investigation, 118, 3003 3006.
11. Holz, M.K., Ballif, B.A., Gygi, S.P. Blenis, J. (2005) mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell, 123, 569 580.
12. Huber, R., Kunisch, E., Gluck, B., Egerer, R., Sickinger, S. Kinne, R.W. (2003) Comparison of conventional and real-time RT-PCR for the quantitation of jun protooncogene mRNA and analysis of junB mRNA expression in synovial membranes and isolated synovial fibroblasts from rheumatoid arthritis patients. Zeitschrift für Rheumatologie, 62, 378 389.
13. Johnson, P.F. (2005) Molecular stop signs: regulation of cell-cycle arrest by C/EBP transcription factors. Journal of Cell Science, 118, 2545 2555.
14. Jundt, F., Raetzel, N., Muller, C., Calkhoven, C.F., Kley, K., Mathas, S., Lietz, A., Leutz, A. Dorken, B. (2005) A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein [beta] and NF-[kappa]B activity in Hodgkin and anaplastic large cell lymphomas. Blood, 106, 1801 1807.
15. Kelly, L.M., Liu, Q., Kutok, J.L., Williams, I.R., Boulton, C.L. Gilliland, D.G. (2002) FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood, 99, 310 318.
16. Kirstetter, P., Schuster, M.B., Bereshchenko, O., Moore, S., Dvinge, H., Kurz, E., Theilgaard-Monch, K., Mansson, R., Pedersen, T.A., Pabst, T., Schrock, E., Porse, B.T., Jacobsen, S.E., Bertone, P., Tenen, D.G. Nerlov, C. (2008) Modeling of C/EBPalpha mutant acute myeloid leukemia reveals a common expression signature of committed myeloid leukemia-initiating cells. Cancer Cell, 13, 299 310.
17. Krauter, J., Hoellge, W., Wattjes, M.P., Nagel, S., Heidenreich, O., Bunjes, D., Ganser, A. Heil, G. (2001) Detection and quantification of CBFB/MYH11 fusion transcripts in patients with inv(16)-positive acute myeloblastic leukemia by real-time RT-PCR. Genes, Chromosomes and Cancer, 30, 342 348.
18. Ma, X.M. Blenis, J. (2009) Molecular mechanisms of mTOR-mediated translational control. Nature Reviews Molecular Cell Biology, 10, 307 318.
19. McCubrey, J.A., Steelman, L.S., Abrams, S.L., Bertrand, F.E., Ludwig, D.E., Basecke, J., Libra, M., Stivala, F., Milella, M., Tafuri, A., Lunghi, P., Bonati, A. Martelli, A.M. (2008) Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia, 22, 708 722.
20. Mikeska, T. Dobrovic, A. (2009) Validation of a primer optimisation matrix to improve the performance of reverse transcription - quantitative real-time PCR assays. BMC Research Notes, 2, 112.
21. Mizuki, M., Schwable, J., Steur, C., Choudhary, C., Agrawal, S., Sargin, B., Steffen, B., Matsumura, I., Kanakura, Y., Bohmer, F.D., Muller-Tidow, C., Berdel, W.E. Serve, H. (2003) Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. Blood, 101, 3164 3173.
22. Murphy, K.M., Levis, M., Hafez, M.J., Geiger, T., Cooper, L.C., Smith, B.D., Small, D. Berg, K.D. (2003) Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay. The Journal of Molecular Diagnostics, 5, 96 102.
23. Nerlov, C. (2007) The C/EBP family of transcription factors: a paradigm for interaction between gene expression and proliferation control. Trends in Cell Biology, 17, 318 324.
24. Nerlov, C. (2008) C/EBPs: recipients of extracellular signals through proteome modulation. Current Opinion in Cell Biology, 20, 180 185.
25. Pabst, T., Mueller, B.U., Zhang, P., Radomska, H.S., Narravula, S., Schnittger, S., Behre, G., Hiddemann, W. Tenen, D.G. (2001) Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nature Genetics, 27, 263 270.
26. Patch, R.J., Baumann, C.A., Liu, J., Gibbs, A.C., Ott, H., Lattanze, J. Player, M.R. (2006) Identification of 2-acylaminothiophene-3-carboxamides as potent inhibitors of FLT3. Bioorganic & Medicinal Chemistry Letters, 16, 3282 3286.
27. Quintanilla-Martinez, L., Pittaluga, S., Miething, C., Klier, M., Rudelius, M., Davies-Hill, T., Anastasov, N., Martinez, A., Vivero, A., Duyster, J., Jaffe, E.S., Fend, F. Raffeld, M. (2006) NPM-ALK-dependent expression of the transcription factor CCAAT/enhancer binding protein beta in ALK-positive anaplastic large cell lymphoma. Blood, 108, 2029 2036.
28. Ramji, D.P. Foka, P. (2002) CCAAT/enhancer-binding proteins: structure, function and regulation. Biochemical Journal, 365, 561 575.
29. Rosenbauer, F. Tenen, D.G. (2007) Transcription factors in myeloid development: balancing differentiation with transformation. Nature Reviews Immunology, 7, 105 117.
30. Sabatini, D.M. (2006) mTOR and cancer: insights into a complex relationship. Nature Reviews. Cancer, 6, 729 734.
31. Schlenk, R.F., Dohner, K., Krauter, J., Frohling, S., Corbacioglu, A., Bullinger, L., Habdank, M., Spath, D., Morgan, M., Benner, A., Schlegelberger, B., Heil, G., Ganser, A. Dohner, H. (2008) Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. The New England Journal of Medicine, 358, 1909 1918.
32. Shahbazian, D., Roux, P.P., Mieulet, V., Cohen, M.S., Raught, B., Taunton, J., Hershey, J.W., Blenis, J., Pende, M. Sonenberg, N. (2006) The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity. The EMBO Journal, 25, 2781 2791.
33. Shurin, M.R., Esche, C. Lotze, M.T. (1998) FLT3: receptor and ligand. Biology and potential clinical application. Cytokine & Growth Factor Reviews, 9, 37 48.
34. Skeen, J.E., Bhaskar, P.T., Chen, C.C., Chen, W.S., Peng, X.D., Nogueira, V., Hahn-Windgassen, A., Kiyokawa, H. Hay, N. (2006) Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner. Cancer Cell, 10, 269 280.
35. Smith, J.A., Poteet-Smith, C.E., Xu, Y., Errington, T.M., Hecht, S.M. Lannigan, D.A. (2005) Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation. Cancer Research, 65, 1027 1034.
36. Steelman, L.S., Abrams, S.L., Whelan, J., Bertrand, F.E., Ludwig, D.E., Basecke, J., Libra, M., Stivala, F., Milella, M., Tafuri, A., Lunghi, P., Bonati, A., Martelli, A.M. McCubrey, J.A. (2008) Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia, 22, 686 707.
37. Stirewalt, D.L. Radich, J.P. (2003) The role of FLT3 in haematopoietic malignancies. Nature Reviews. Cancer, 3, 650 665.
38. Thiede, C., Steudel, C., Mohr, B., Schaich, M., Schakel, U., Platzbecker, U., Wermke, M., Bornhauser, M., Ritter, M., Neubauer, A., Ehninger, G. Illmer, T. (2002) Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood, 99, 4326 4335.
39. Weisberg, E., Roesel, J., Bold, G., Furet, P., Jiang, J., Cools, J., Wright, R.D., Nelson, E., Barrett, R., Ray, A., Moreno, D., Hall-Meyers, E., Stone, R., Galinsky, I., Fox, E., Gilliland, G., Daley, J.F., Lazo-Kallanian, S., Kung, A.L. Griffin, J.D. (2008a) Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells. Blood, 112, 5161 5170.
40. Weisberg, E., Banerji, L., Wright, R.D., Barrett, R., Ray, A., Moreno, D., Catley, L., Jiang, J., Hall-Meyers, E., Sauveur-Michel, M., Stone, R., Galinsky, I., Fox, E., Kung, A.L. Griffin, J.D. (2008b) Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells. Blood, 111, 3723 3734.
41. Welm, A.L., Timchenko, N.A. Darlington, G.J. (1999) C/EBPalpha regulates generation of C/EBPbeta isoforms through activation of specific proteolytic cleavage. Molecular and Cellular Biology, 19, 1695 1704.
42. Xiong, W., Hsieh, C.C., Kurtz, A.J., Rabek, J.P. Papaconstantinou, J. (2001) Regulation of CCAAT/enhancer-binding protein-beta isoform synthesis by alternative translational initiation at multiple AUG start sites. Nucleic Acids Research, 29, 3087 3098.
43. Zahnow, C.A., Younes, P., Laucirica, R. Rosen, J.M. (1997) Overexpression of C/EBPbeta-LIP, a naturally occurring, dominant-negative transcription factor, in human breast cancer. Journal of the National Cancer Institute, 89, 1887 1891.
44. Zahnow, C.A., Cardiff, R.D., Laucirica, R., Medina, D. Rosen, J.M. (2001) A role for CCAAT/enhancer binding protein beta-liver-enriched inhibitory protein in mammary epithelial cell proliferation. Cancer Research, 61, 261 269.
45. Zwergal, A., Quirling, M., Saugel, B., Huth, K.C., Sydlik, C., Poli, V., Neumeier, D., Ziegler-Heitbrock, H.W. Brand, K. (2006) C/EBP beta blocks p65 phosphorylation and thereby NF-kappa B-mediated transcription in TNF-tolerant cells. The Journal of Immunology, 177, 665 672.